恩华药业(002262.SZ)发布上半年业绩，归母净利润7亿元，增长11.38%

Financial Performance - The company reported a revenue of 3.01 billion yuan for the first half of 2025, representing a year-on-year increase of 8.93% [1] - The net profit attributable to shareholders was 700 million yuan, showing a year-on-year growth of 11.38% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 699 million yuan, with a year-on-year increase of 10.33% [1] - The basic earnings per share were 0.69 yuan [1] Research and Development - The company has over 70 ongoing research projects, with a research expenditure of 395 million yuan, which is a 23.97% increase compared to the same period last year [2] - In the field of innovative drug development, there are currently 17 innovative drug projects under research, including 1 project that has completed Phase III clinical trials and 2 projects that have completed Phase II clinical trials [2] - The company is conducting 48 projects in generic drug development, with 1 project having received production approval and 5 projects currently under review for production approval [2]